Eli Lilly and Company (LLY)

Eli Lilly & Co.'s stock price has seen a 0.58% rise in the past six months, but has decreased by 14.91% over the last year. Recent events impacting the stock include plans to acquire Verve Therapeutics, offering Zepbound through LillyDirect, FDA approval of Zepbound, and acquisitions of Emergence Therapeutics, Sigilon Therapeutics, Versanis, and Point Biopharma in 2023. Recent declines in stock price have been attributed to market reactions to earnings reports, slowdowns in sales growth, cautious future guidance, economic conditions, competition, and regulatory challenges.

While specific demand seasonality for Eli Lilly products is not detailed, historical data suggests July tends to be a positive month for LLY stock. The company manages its supply chain to meet expected product demand and maintain flexibility.

Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, founded in 1876. It operates in the Healthcare sector, focusing on the discovery, development, manufacturing, and commercialization of human pharmaceutical products. Lilly's product portfolio addresses endocrinology, immunology, oncology, neuroscience, and cardiovascular health, with key products including treatments for diabetes, obesity, cancer, neurological disorders, and immune-related conditions.

Eli Lilly & Co. has a significant global presence with offices in 18 countries and product sales in approximately 125 countries. Its operations span across North America, South America, Europe, the Middle East, Africa, and Asia-Pacific, with research and development facilities in 7 countries and manufacturing facilities in 9 countries. The United States is the largest contributor to Eli Lilly's revenue, accounting for 67.44% of its total revenue in fiscal year 2024, followed by Europe (15.36%), Japan (4.02%), and China (3.69%). In September 2024, Lilly announced a $1 billion expansion of its Limerick, Ireland manufacturing site and unveiled a new $800 million facility expansion in Kinsale, Ireland, to boost production of biologic active ingredients for treatments in areas like Alzheimer's disease, diabetes, and obesity.

Eli Lilly has a strong reputation for research and development and corporate responsibility. However, increased scrutiny on sustainability, regulatory compliance, economic conditions, and competition can impact the company's brand and reputation.

Eli Lilly & Co. is primarily owned by institutional shareholders, who hold 86.74% of the company's stock. Insiders own 10.93%, and retail investors hold 2.33%. Major shareholders include Lilly Endowment Inc., PNC Financial Services Group Inc., Vanguard Group Inc., and BlackRock Inc.